High Neutrophil Count on Lithium: Not a Safety Concern
Neutrophilia (elevated neutrophil count) during lithium therapy is an expected, benign pharmacological effect and is not a safety concern. This is a well-established hematological response to lithium and does not require treatment modification or discontinuation 1.
Understanding Lithium-Induced Neutrophilia
Lithium predictably causes leukocytosis, primarily through neutrophilia, by enhancing granulopoiesis. This effect occurs through:
- Direct stimulation of pluripotent stem cells
- Possible inhibition of suppressor T-lymphocytes that normally limit hematopoiesis 2
- Enhancement of granulocyte colony-stimulating factor (G-CSF) effects 3
All patients on lithium manifest neutrophilia during administration 4. This is not pathological—it's a therapeutic property that has even been investigated for treating neutropenic conditions 3, 5.
What Monitoring Is Actually Required
The FDA-approved lithium label lists "leukocytosis" as a miscellaneous reaction unrelated to dosage 1. Guidelines for lithium monitoring focus on:
Before starting lithium 6:
- Complete blood count (baseline)
- Thyroid function tests
- Renal function (BUN, creatinine, urinalysis)
- Serum calcium
- Pregnancy test in females
During maintenance therapy 6:
- Lithium levels every 3-6 months
- Renal and thyroid function every 3-6 months
- Urinalysis every 3-6 months
Notably absent: Routine CBC monitoring during stable lithium therapy is not recommended in guidelines 6. The baseline CBC before lithium initiation may be useful to assess any pre-existing neutropenia caused by the underlying psychiatric condition itself 7, but ongoing neutrophil monitoring is unnecessary.
When Neutrophil Counts Actually Matter
The only hematological concern with lithium is if a patient develops neutropenia (low counts), not neutrophilia. Even then:
- Neutrophil function remains normal during lithium therapy 8
- Lithium has been successfully used to treat chemotherapy-induced neutropenia 5
- Lithium can support hematological stability even in patients with prior clozapine-induced neutropenia 9
Clinical Bottom Line
Do not reduce or discontinue lithium because of elevated neutrophil counts. This represents normal lithium pharmacology, not toxicity. Focus monitoring efforts on:
- Lithium levels (target 0.6-1.2 mEq/L for maintenance; avoid >1.5 mEq/L) 1
- Renal function (lithium nephropathy and nephrogenic diabetes insipidus are real concerns) 1, 10
- Thyroid function (hypothyroidism is common) 1
- Clinical signs of lithium toxicity (tremor, confusion, ataxia, GI symptoms) 1
The neutrophilia you're observing is evidence that lithium is having its expected hematological effect—nothing more.